AzTrials
AzTrials

tDCSNCT07625566

Anodal tDCS Over Left PPC Enhances Visuospatial Attention and Alpha Power Among Young Adults

A study testing Anodal tDCS in people with tDCS and Posterior Parietal Cortex, run by Medipol University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Visuospatial attention enables individuals to detect and process relevant stimuli efficiently. The posterior parietal cortex (PPC), a core hub of the dorsal attention network, exerts top-down control over visual scanning and is closely linked to alpha-band oscillations (8-13 Hz), which index attentional… Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
tDCS, Posterior Parietal Cortex, Visual Attention
What is being tested?
Anodal tDCS
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
32 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Feb 2021to 1 Nov 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age between 18 and 40 years
  • Score of 21 or higher on the Montreal Cognitive Assessment Scale (MoCA)

Who cannot join

  • History of neurological or psychiatric illness
  • Uncorrected visual impairments
  • MoCA score of 21 or lower
  • Use of medications affecting cortical excitability
  • History of seizures or epilepsy
  • Presence of intracranial metal objects, implanted stimulating devices, or pacemakers

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Istanbul Medipol University

    Beykoz, İ̇stanbul, 34820

Other trials in Turkey (Türkiye)

About this study

Background: Visuospatial attention enables individuals to detect and process relevant stimuli efficiently. The posterior parietal cortex (PPC), a core hub of the dorsal attention network, exerts top-down control over visual scanning and is closely linked to alpha-band oscillations (8-13 Hz), which index attentional allocation and inhibition of distractors. Transcranial direct current stimulation (tDCS) offers a noninvasive method to alter cortical excitability transiently, but evidence for its effects on PPC-mediated attention and alpha power remains mixed.

Objective: This randomized, single-blind trial examined whether anodal tDCS over the left PPC modulates visuospatial attention and resting-state alpha power in young adults, and whether EEG changes predict behavioral performance.

Method: Thirty-two healthy participants (18-40 years) were randomized to anodal (2 mA, 20 min; n=15) or sham (n=17) stimulation. Cancellation Test performance and resting-state EEG were assessed pre- and post-stimulation. EEG analyses focused on artifact-free alpha power; regression models probed associations between neural and behavioral changes.

Being tested
Anodal tDCS, Sham tDCS
Keywords
tDCS, posterior parietal cortex, visuospatial attention, EEG alpha oscillations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Anodal tDCSDevice

    Anodal tDCS Protocol: In the Anodal tDCS participant group, a direct current of 2 mA was applied for 20 minutes in accordance with the safety guidelines. To provide cortical stimulation, the superficial anodal electrode of the device was placed on the P3 region (left PPC), which is located in the left superior parietal lobe, corresponds to Brodmann area (BA) 40, and is associated with the dorsal visual pathway according to the international 10-20 EEG system. The reference electrode was placed on the contralateral (opposite) shoulder.

  • Sham tDCSDevice

    Sham tDCS Protocol: The anode superficial electrode of the device was placed on the P3 region (left PPC), located in the left superior parietal lobe, corresponding to Brodmann area (BA) 40, and associated with the dorsal visual pathway according to the international 10-20 EEG system. The reference electrode was placed on the contralateral (opposite) shoulder. In the Sham tDCS group, a single 20-minute sham session was administered over the left posterior parietal cortex (P3) without delivering current, in accordance with the safety guidelines.

Study groups in NCT07625566
Study groupRoleWhat they receive
Anodal tDCS GroupExperimentalNot described
Receives: Device: Anodal tDCS
Sham tDCS GroupSham comparatorNot described
Receives: Device: Sham tDCS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. EEG recording and power in alpha band

    EEG recordings were acquired in a semi-dark, electrically shielded Faraday room using a BrainAmp 32-Channel DC System (Brain Products, Munich, Germany). Signals were sampled at 500 Hz with a 0.01-250 Hz bandpass filter and recorded using BrainVision Recorder software. A 32-channel Ag/AgCl electrode cap (Easycap) was positioned according to the international 10-20 system. Resting-state EEG data were collected for 4 minutes with eyes open and 4 minutes with eyes closed. Numerical evaluation of artifact-free EEG data for power density calculation is performed using Fast Fourier Transform (FFT) with 0.5 Hz frequency resolution, and alpha (8-13 Hz) bands were calculated and then averaged over these power spectrum values. The amplitude values, measured from peak to peak, were recorded for each individual, and the necessary data for statistical analysis were collected.

    Measured: Before and immediately after applying tDCS

  2. Cancellation Test

    The Cancellation Test is one of the most widely used tools for assessing visuospatial attention. IT consists of four subtests arranged on A4-sized sheets. Each subtest includes 60 target stimuli distributed among 300 total stimuli. For each subtest, separate scores are calculated for the right and left sides, including the number of correctly marked targets (IT1), omitted targets (IT2), incorrectly marked letters/shapes (IT3), total error score (IT4), and scanning time (IT5). The total error score is calculated as the sum of omitted targets and incorrectly marked letters/shapes. Achieving a high score (i.e., a high number of correctly marked targets and a low number of errors) and a short completion time (time score) indicate better performance. İn the present study, the paper-and-pencil version of the Cancellation Test was chosen to reliably assess visuospatial attention and subtle tDCS-induced changes.

    Measured: Before and immediately after applying tDCS

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2026
  2. Study start1 Feb 2021
  3. Primary completion1 Jul 2021
  4. Study completion1 Nov 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07625566
Sponsor's protocol ID
E-10840098-772.02-605
Status last verified
May 2026
First submitted
22 May 2026
Last updated
4 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Anodal tDCS in people with tDCS and Posterior Parietal Cortex, run by Medipol University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

EEG recording and power in alpha band (time frame: Before and immediately after applying tDCS). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in